



ASX ANNOUNCEMENT

8 March 2022

## Extension of Closing Date for Retail Entitlement Offer

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric** or **Company**) announced the details of an accelerated non-renounceable entitlement offer (**Entitlement Offer**) to raise approximately \$18.1 million (before the exercise of any new options).

Under the Entitlement Offer, eligible retail shareholders are able to subscribe for 1 new fully paid ordinary share in Chimeric (**New Share**) (and 1 new option for every New Share issued with an exercise price of \$0.255 per new option and exercisable on or before 31 March 2024<sup>1</sup> (**New Option**)) for every 3.15 fully paid ordinary shares in Chimeric held as at 7pm (Sydney time) on Wednesday, 23 February 2022 at the issue price of \$0.17 per New Share.

The Entitlement Offer includes an institutional component (**Institutional Entitlement Offer**) and a retail component (**Retail Entitlement Offer**). Chimeric announced the successful completion of the Institutional Entitlement Offer on 23 February 2022.

### Extension of Closing Date for Retail Entitlement Offer

Chimeric advises that the Closing Date of the Retail Entitlement Offer has been extended by seven days to 5:00 pm (Sydney time) on Friday, 18 March 2022 (**Extended Closing Date**). The Extended Closing Date is to ensure all eligible retail shareholders have an additional opportunity to participate in the Retail Entitlement Offer.

### Revised indicative timetable<sup>2</sup>

The Extended Closing Date will have a consequential effect on the indicative timetable, including the date of allotment and issue of the New Shares and New Options under the Retail Entitlement Offer and the New Options under the Institutional Entitlement Offer which is now anticipated to occur on 5:00 pm (Sydney time) on Friday, 25 March 2022. The expiry date of the New Options will remain 31 March 2024.

---

<sup>1</sup> Eligible institutional shareholders must, at the issuance date of the New Options, hold at least the number of New Shares they subscribed for under the Institutional Entitlement Offer.

<sup>2</sup> All dates are indicative only and subject to change. Chimeric reserves the right to withdraw or vary the timetable without notice.



Event	Date
Announcement of the Entitlement Offer	21 February 2022
Record Date for Retail Entitlement Offer (7.00pm, Sydney time)	23 February 2022
Prospectus and entitlement and acceptance form despatched to Eligible Retail Shareholders	28 February 2022
Retail Entitlement Offer opens	28 February 2022
Retail Entitlement Offer closes (5.00pm, Sydney time)	18 March 2022
Announcement of results of Retail Entitlement Offer and under-subscriptions	23 March 2022
Allotment of New Shares and New Options issued under the Retail Entitlement Offer	25 March 2022
Allotment of New Options under the Institutional Entitlement Offer	25 March 2022
Despatch of holding statements for New Shares and New Options issued under the Retail Entitlement Offer, and New Options issued under the Institutional Entitlement Offer	28 March 2022
Normal ASX trading for New Shares and New Options issued under the Retail Entitlement Offer, and New Options under the Institutional Entitlement Offer, commences	28 March 2022

### Electronic access

The prospectus (**Prospectus**) under which the Entitlement Offer is made is available at [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com). The entitlement and acceptance form attached to the electronic version of the Prospectus must be used within Australia or New Zealand.

### For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).

This announcement has been authorised by the Board of Chimeric.

Phillip Hains  
Company Secretary

### Important information

**This document must not be distributed or released in the United States.**